Kiniksa Pharmaceuticals has recently updated its 2025 revenue guidance for ARCALYST, projecting net product revenue of $605 million. This revision comes in light of the strong performance reported during the first quarter of 2025, where the company saw significant sales growth.
The previous revenue forecast was set between $560 million and $580 million, but the increase to $605 million reflects Kiniksa's confidence in the growing market penetration of ARCALYST. By the end of Q1 2025, about 13% of the target population of 14,000 patients suffering from multiple-recurrence pericarditis were on ARCALYST treatment. This indicates a promising adoption rate, contributing to the company's positive financial outlook.
The company, operating under the stock symbol KNSA in the USA market, is seeing its stock priced at $25.89, with a movement of $4.42 since the previous close. The market seems to respond to the revised guidance with interest, as reflected in the intraday volume and trading activity. Kiniksa anticipates remaining cash flow positive annually, signaling a strong financial foundation and sustained business growth.